Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Mercy Hospital
198
mi
from
Kansas City, MO
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Mercy Hospital
198
mi
from
Kansas City, MO
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of New Mexico Cancer Center
522
mi
from
Albuquerque, NM
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of New Mexico Cancer Center
522
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
726
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Nationwide Children's Hospital
811
mi
from
Columbus, OH
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Mercy Children's Hospital
805
mi
from
Toledo, OH
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Mercy Children's Hospital
805
mi
from
Toledo, OH
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Randall Children's Hospital at Legacy Emanuel
1383
mi
from
Portland, OR
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Randall Children's Hospital at Legacy Emanuel
1383
mi
from
Portland, OR
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
BI-LO Charities Children's Cancer Center
880
mi
from
Greenville, SC
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
BI-LO Charities Children's Cancer Center
880
mi
from
Greenville, SC
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
East Tennessee Children's Hospital
778
mi
from
Knoxville, TN
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
East Tennessee Children's Hospital
778
mi
from
Knoxville, TN
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Virginia Commonwealth University Massey Cancer Center
1113
mi
from
Richmond, VA
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Virginia Commonwealth University Massey Cancer Center
1113
mi
from
Richmond, VA
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital of Alabama
684
mi
from
Birmingham, AL
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital of Alabama
684
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham Cancer Center
684
mi
from
Birmingham, AL
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham Cancer Center
684
mi
from
Birmingham, AL
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
370
mi
from
Little Rock, AR
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
370
mi
from
Little Rock, AR
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Loma Linda University Medical Center
1114
mi
from
Loma Linda, CA
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Loma Linda University Medical Center
1114
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Miller Children's and Women's Hospital Long Beach
1171
mi
from
Long Beach, CA
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Miller Children's and Women's Hospital Long Beach
1171
mi
from
Long Beach, CA
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
UCSF Medical Center at Parnassus
1341
mi
from
San Francisco, CA
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
UCSF Medical Center at Parnassus
1341
mi
from
San Francisco, CA
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
409
mi
from
Denver, CO
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center
409
mi
from
Denver, CO
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Yale University
1344
mi
from
New Haven, CT
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Yale University
1344
mi
from
New Haven, CT
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Lee Memorial Health System
1209
mi
from
Fort Myers, FL
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Lee Memorial Health System
1209
mi
from
Fort Myers, FL
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Nemours Children's Clinic - Jacksonville
1058
mi
from
Jacksonville, FL
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Nemours Children's Clinic - Jacksonville
1058
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Nicklaus Children's Hospital
1317
mi
from
Miami, FL
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Nicklaus Children's Hospital
1317
mi
from
Miami, FL
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Florida Hospital Orlando
1141
mi
from
Orlando, FL
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Florida Hospital Orlando
1141
mi
from
Orlando, FL
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins All Children's Hospital
1117
mi
from
Saint Petersburg, FL
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins All Children's Hospital
1117
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Healthcare of Atlanta - Egleston
803
mi
from
Atlanta, GA
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Healthcare of Atlanta - Egleston
803
mi
from
Atlanta, GA
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Memorial University Medical Center
1023
mi
from
Savannah, GA
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Memorial University Medical Center
1023
mi
from
Savannah, GA
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Hawaii Cancer Center
3717
mi
from
Honolulu, HI
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Hawaii Cancer Center
3717
mi
from
Honolulu, HI
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Chicago Comprehensive Cancer Center
610
mi
from
Chicago, IL
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Chicago Comprehensive Cancer Center
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Riley Hospital for Children
643
mi
from
Indianapolis, IN
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Riley Hospital for Children
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Saint Vincent Hospital and Health Care Center
642
mi
from
Indianapolis, IN
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Saint Vincent Hospital and Health Care Center
642
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Kentucky, Markey Cancer Center
725
mi
from
Lexington, KY
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Kentucky, Markey Cancer Center
725
mi
from
Lexington, KY
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Ochsner Medical Center Jefferson
694
mi
from
New Orleans, LA
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Ochsner Medical Center Jefferson
694
mi
from
New Orleans, LA
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Sinai Hospital of Baltimore
1145
mi
from
Baltimore, MD
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Sinai Hospital of Baltimore
1145
mi
from
Baltimore, MD
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
1444
mi
from
Boston, MA
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
1444
mi
from
Boston, MA
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Wayne State University/Karmanos Cancer Institute
841
mi
from
Detroit, MI
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Wayne State University/Karmanos Cancer Institute
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Minnesota, Masonic Cancer Center
552
mi
from
Minneapolis, MN
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Minnesota, Masonic Cancer Center
552
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
515
mi
from
Rochester, MN
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
515
mi
from
Rochester, MN
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
University of Mississippi Medical Center
571
mi
from
Jackson, MS
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
University of Mississippi Medical Center
571
mi
from
Jackson, MS
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine
414
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital Saint Louis
405
mi
from
Saint Louis, MO
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital Saint Louis
405
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Children's Hospital and Medical Center of Omaha
262
mi
from
Omaha, NE
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Children's Hospital and Medical Center of Omaha
262
mi
from
Omaha, NE
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Hackensack University Medical Center
1285
mi
from
Hackensack, NJ
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Hackensack University Medical Center
1285
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Morristown Medical Center
1262
mi
from
Morristown, NJ
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Morristown Medical Center
1262
mi
from
Morristown, NJ
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Overlook Hospital
1268
mi
from
Summit, NJ
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Overlook Hospital
1268
mi
from
Summit, NJ
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Columbia University Herbert Irving Cancer Center
1290
mi
from
New York, NY
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Columbia University Herbert Irving Cancer Center
1290
mi
from
New York, NY
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
1289
mi
from
New York, NY
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Stony Brook University Medical Center
1358
mi
from
Stony Brook, NY
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Stony Brook University Medical Center
1358
mi
from
Stony Brook, NY
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
UNC Lineberger Comprehensive Cancer Center
1038
mi
from
Chapel Hill, NC
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
UNC Lineberger Comprehensive Cancer Center
1038
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Carolinas Medical Center / Levine Cancer Institute
958
mi
from
Charlotte, NC
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Carolinas Medical Center / Levine Cancer Institute
958
mi
from
Charlotte, NC
Click here to add this to my saved trials
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated:  12/31/1969
Novant Health Presbyterian Medical Center
958
mi
from
Charlotte, NC
Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
A Phase II Study of Cixutumumab (IMC-A12) in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
Status: Enrolling
Updated: 12/31/1969
Novant Health Presbyterian Medical Center
958
mi
from
Charlotte, NC
Click here to add this to my saved trials